#SFHS2614506AFrance Adds ESKAZOLE 400 mg to the Reimbursable Medicines List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
ESKAZOLE 400 mg, an albendazole tablet supplied in bottles of 60, is added to France’s list of medicines reimbursed by health insurance. Reimbursement applies only for the therapeutic uses covered by its marketing authorization on the date the order is published. This mainly affects patients prescribed ESKAZOLE, pharmacies, prescribers, and the manufacturer GlaxoSmithKline. The change takes effect on the fourth day after publication in the French Official Journal.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds ESKAZOLE 400 mg albendazole tablets to the list of medicines reimbursed by French health insurance
- Limits reimbursement to therapeutic indications covered by the marketing authorization at the publication date
- Sets the effective date as the fourth day after publication in the French Official Journal
Obligations
What this law requires
Health insurance reimbursement for ESKAZOLE 400 mg (albendazole), tablets in HDPE bottle of 60, CIP 34009 368 674 2 0, must be limited to the therapeutic indications included in its marketing authorization on the publication date of the order.
ESKAZOLE 400 mg (albendazole), tablets in HDPE bottle of 60, CIP 34009 368 674 2 0, must be treated as included on the list of pharmaceutical specialties reimbursable to insured persons under Article L. 162-17.